Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Alpha-gal syndrome (AGS), a tick-bite-triggered allergy to red meat and mammalian products, may have a new management tool. A retrospective study of 64 high-risk AGS patients found that omalizumab (Xolair) eliminated the need for epinephrine during treatment and meaningfully reduced reaction burden in 95% of patients. A third of patients were even able to partially or fully reintroduce mammalian foods into their diet.
Alpha-gal syndrome (AGS) — a delayed allergic reaction to red meat and mammalian products triggered by lone star tick bites — can be debilitating, with patients facing unpredictable anaphylaxis even with strict dietary avoidance. A new retrospective study presented at the ACAAI Annual Scientific Meeting suggests that omalizumab (Xolair), an anti-IgE biologic, may offer meaningful relief for high-risk patients who continue to struggle despite avoidance measures.
Researchers at UNC Chapel Hill analyzed 64 confirmed AGS patients (median age 55; 56% female) treated with omalizumab for a median of 23 months. At baseline, 81% had documented anaphylaxis and 53% had required epinephrine — making this a notably high-risk cohort. During treatment, not a single patient needed epinephrine for a food-triggered reaction, and 95% reported a clinically meaningful reduction in reaction frequency or severity.
By the Numbers:
Why it matters: While omalizumab is not a cure for AGS and avoidance remains the cornerstone of management, these findings suggest anti-IgE therapy could serve as a meaningful safety net — reducing anaphylaxis risk, epinephrine dependence, and dietary anxiety for carefully selected patients. Prospective, multicenter trials are now needed to confirm these results and define optimal dosing strategies.